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Retinoic acid (RA) is a potent teratogen in all vertebrates when tight homeostatic controls on its endogenous dose,
location, or timing are perturbed during early embryogenesis. STRA6 encodes an integral cell-membrane protein that
favors RA uptake from soluble retinol-binding protein; its transcription is directly regulated by RA levels. Molecular
analysis of STRA6 was undertaken in two human fetuses from consanguineous families we previously described with
Matthew-Wood syndrome in a context of severe microphthalmia, pulmonary agenesis, bilateral diaphragmatic eventra-
tion, duodenal stenosis, pancreatic malformations, and intrauterine growth retardation. The fetuses had either a ho-
mozygous insertion/deletion in exon 2 or a homozygous insertion in exon 7 predicting a premature stop codon in STRA6
transcripts. Five other fetuses presenting at least one of the two major signs of clinical anophthalmia or pulmonary
hypoplasia with at least one of the two associated signs of diaphragmatic closure defect or cardiopathy had no STRA6
mutations. These ﬁndings suggest a molecular basis for the prenatal manifestations of Matthew-Wood syndrome and
suggest that phenotypic overlap with other associations may be due to genetic heterogeneity of elements common to
the RA- and ﬁbroblast growth factor–signaling cascades.
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Microphthalmia refers to a clinical spectrum that is char-
acterized by a congenital reduction in the size of the optic
globe(s), which may be reduced to a vestige visible only
on histological analysis. This most severe form of micro-
phthalmia is sometimes called “secondary” or “clinical”
anophthalmia and occurs later in development than pri-
mary anophthalmia because of a lack of optic vesicle for-
mation from the embryonic prosencephalon. Isolated se-
vere microphthalmia/anophthalmia demonstrates both
genetic and phenotypic heterogeneity in humans, cur-
rently implicating genes coding for transcription factors.
CHX10mutations lead tomicrophthalmia, coloboma,and
cataracts1,2; mutations in the RAX gene have been iden-
tiﬁed in an individual with unilateral anophthalmia and
sclerocornea in the other eye.3 PAX6 mutations lead to
diverse congenital ocular malformations, the most com-
mon of which is aniridia, but a few genotypes have been
described to date that engender primary anophthalmia4
or microphthalmia,5–7 as documented in the PAX Allelic
Variant Database.
Syndromic microphthalmias (MIM 164180, 206900,
206920, 248450, 300166, 301590, 309801, 600776,
605856, 607932, 610125, 610126, and 601349) can be as-
sociated with craniofacial dysmorphic features, heart and
vascular malformations, skeletal and limb anomalies, skin
or gut defects, mental retardation, and hydrocephalus, or
combinations thereof. Although rare, the association of
severe microphthalmia and pulmonary hypoplasia (MIM
601186) is a distinct entity known as “Matthew-Wood
syndrome” (MWS [MIM 601186]).8 Most authors have re-
ported further associations of MWS with cardiac and/or
diaphragmatic malformations and intrauterine growth re-
tardation (IUGR).9–13
In two familial cases of MWS, we have excluded mu-
tations in the FGF10 and FGFR2IIIb genes encoding ﬁbro-
blast growth factor 10 and its speciﬁc receptor isoform.14
These proteins are essential for the development of all
affected organs in MWS.15–17 Meanwhile, STRA6 gene mu-
tations were recently implicated in heterogeneous post-
natal associations of clinical anophthalmia, pulmonary
hypoplasia, diaphragmatic hernia, and cardiac defects.18 A
molecular analysis of the STRA6 gene was undertaken in
the two families with MWS we had described,14 as well as
in ﬁve other fetuses presenting at least one of the two
major signs of clinical anophthalmia or pulmonary hy-
poplasia and at least one of the two associated signs of
diaphragmatic closure defect or cardiopathy.
In all seven fetuses examined, the presence of severe
malformations was noted on ultrasound examination,
and, after genetic counseling, pregnancies were inter-
rupted. Clinical data are summarized in table 1. Chro-
mosome and molecular analyses and pathological exam-
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Table 1. Overview of Clinical Features in Cases Undergoing STRA6 Molecular Analysis from Our Series and Pasutto et al.18
Case
STRA6
Mutation(s)
Clinical Featuresa
Age at Death ConsanguinityEyes Lungs Diaphragm Cardiovascular Face Other Growth
Fetus 1b p.D17A fsX55 Bi AO Bi agenesis Bi eventr Bi absence of PA
branches
Mild dysmorphism Duodenal stenosis, annular pancreas IUGR 31 wg Yes, recurrence
Fetus 2b p.G176G fsX59 Bi AO Bi agenesis Bi eventr Pulmonary trunk
and PA absence,
VSD
Mild dysmorphism Duodenal stenosis, absent
pancreas, polylobed spleen
IUGR 28 wg Yes
Fam2-IV:1 p.G50A fsX22 Bi AO … CDH ASD, VSD Mild dysmorphism MR SS Alive at 14
years
Yes, recurrence
Fam2-IV:3 (sib) p.G50A fsX22 Bi AO NA CDH NA Mild dysmorphism NA … 23 wg …
MWS4-BE p.T644M Bi AO Hypo CDH … … Bi hydronephrosis … Alive at 3 mo No, recurrence
Brother MWS4-BE NA NA Hypo unilobar … Fallot, PDA … Horseshoe kidney, undescended testes … 1 d …
Sister MWS4-BE NA Bi AO Hypo unilobar … PDA, CoA … Uterine dysplasia … 1 d …
MWS1-EE p.R655C Bi AO Hypo Uni eventr … … Hypotonia uni inguinal hernia … 3 mo Yes, recurrence
Brother MWS1-EE NA Bi AO … … TA, RAA, PDA, PA
atresia
… … SS 22 mo …
MWS6-BK p.P90L, p.T321P Bi AO Hypo CDH, uni eventr PDA … Hypo kidneys, bicornuate uterus PTB (36 wg) 1 d Yes, recurrence?
Fam1-IV:2 p.P293L Bi AO ACD … PSt, PDA Mild dysmorphism Ectopic kidney, DD PTB (33 wg) 6 mo Yes, recurrence
Fam1-IV:4 (cousin) NA Bi AO NA … Single ventricle PA
atresia
NA … … 2 d …
CD50396b … Bi AO Hypo Uni eventr VSD CP hypo alae nasi Hypo bicornuate uterus, hypo spleen … 1 d No
Fetus 3c … Bi AO Hypo Bi CDH Hypo L ventricle
and aorta, mitral
valve atresia,
VSD
CP CC agenesis, arhinencephaly,
Dandy-Walker
… 16 wg No
Fetus 4 … Uni AO … … Single ventricle
tricuspid valve
atresia, ASD
… Arhinencephaly … 22 wg No
MWS3-KH … Bi MO/AO … CDH … … … … NA No
RHP006.070 … Bi MO/AO … Bi eventr … … MR … NA No
PB-E03_053 … Bi MO/AO … CDH … Brachycephaly MR, sparse hair, bi inguinal hernia … Alive at 10
years
No
GM23728 … Bi MO, abnormal
cornea and iris
Hypo unilobar Hypo, uni eventr Hypo PA CoA … Renal dysplasia … Neonatal No
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AS20861-FF264 … Uni MO … CDH … … Ocular cyst, DD … Alive at 13 mo No
MWS2-FA … Bi coloboma … CDH … … Skin patches, brittle hair … NA Yes
MWS5-LR … Coloboma … CDH … … … … NA No
Fetus 5 … … Hypo Uni CDH Dextroposed aorta
over VSD
… SUA … 32 wg No
AvdW22260 … … Hypo CDH … … … PTB (28 wg) 1 d No
Twin 2 AvdW22260 … … Hypo CDH … CP … PTB (28 wg) 1 d …
PM22479d … … … CDH … Hypertelorism Hypo CC omphalocoele … Neonatal Yes, recurrence
Brotherd PM22479 NA … … CDH ASD Bi CLP,
hypertelorism
Hypo CC … Neonatal …
Fetus 6 … … Bi hypo L agenesis, R
eventr
Hypo L heart … Polysplenia renal dysplasia, SUA IUGR 30 wg No
Fetus 7 … … Bi agenesis … L atrial isomerism,
R ventricular
anomaly
… Polysplenia renal agenesis … 24 wg No
NOTE.—NA p not available. Fetuses 1–7 from our series are highlighted in bold.
a ACD p alveolar capillary dysplasia; AO p clinical anophthalmia; ASD p atrial septal defect; bi p bilateral; CC p corpus callosum; CoA p coarctation of aorta; C(L)P p cleft (lip and) palate; DD p developmental delay;
eventr p eventration; Fallot p tetralogy of Fallot; hypo p hypoplasia; L p left; MO p microphthalmia; MR p mental retardation; PA p pulmonary artery; PDA p patent ductus arteriosus; PSt p pulmonary valve stenosis; PTB
p preterm birth; R p right; RAA p right aortic arch; SS p postnatal short stature; SUA p single umbilical artery; TA p truncus arteriosus; uni p unilateral; VSD p ventricular septal defect; wg p weeks gestation.
b Cases given diagnosis of Matthew-Wood syndrome.
c Cases given diagnosis of Fryns syndrome.
d Cases with suspected Donnai-Barrow syndrome.
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Table 2. STRA6 Oligonucleotides Used for Sequencing
Exon(s)
Oligonucleotide Sequences (5′r3′)
Forward Reverse
1a GGGGTGGGTTCCTCTGAT CACCCCAGGTCTCCAAACT
1b GCTGAAGGCAGGTATGTGTG CCTCTCGTGTCCCCTCCT
2 AAGCCTCTTTTCACATCTGTAGTG CAGTTGCAACCTCTGCCATC
3 TGGGTAAAGCCTCAGTGTGA GTTGGACTTGCATCCTGGTT
4 CAAGCCCTCAAACTCAGACC TGGGGGTCCTGACTAAACCT
5 CCACCTCCTTGATTTATGGAA GCATCGTTGTAAAGACTGGATG
6 and 7 ACCTTCTCATTTTGCCCTTG CTCAAAGGAGGCACTGTGGT
8 GCAACGGATTCTGGTTCTTG GGAGTAGGGCTGTCTTGGG
9 and 10 ACGAATGGGTCGAGGCAG TCTGTGCAAGGGAGGGTAAC
11 CTTGGGAGGGAGGAGGG GGTTGAGGGCAGGGCTC
12 CCAGCGTCTCCCCTGTTAG CATAGACCTTGGGTCTCCCC
13 TGGCAGGGGTTCTGAGG CACAGGACTCCCACTCCTTC
14 TGGCCCAGAGGAGGATTTAG CCAACTGAGGCCAGTGTCTG
15 and 16 AAAGCCCTTGGTTCTGGG ACACCGAAGAAGAGGCGAG
17 AGGTCTGACACTGACCCTGG GATGCCTTCCTCACTGCTTG
18 TGGATGCCTCCAGTGTGG AGGGGCACACATCCTTCC
19 GATCAGGTCTGAGGGCCAG GAGGAGGATGGTAGGCAGG
NOTE.—The annealing temperature for PCR was 60C for all primers.
For QMPSF, ﬂuorescent primers corresponding to STRA6 exon 13 were
used, and MLH1 was chosen as a reference (GTAGTCTGTGATCTCCGTTT, 5′;
ATGTATGAGGTCCTGTCCT, 3′). Coampliﬁcation was performed for 21 cycles,
and the peaks were integrated and proportional DNA copy numbers were
estimated with the use of Genotyper 3.7 software (Applied Biosystems).
Figure 1. Pedigrees of cases 1 and 2, with markers ﬂanking the STRA6 gene, and electropherograms. Case 1 (blue arrow) had a
homozygous insertion/deletion in exon 2 of STRA6 (c.50_52delACTinsCC p.AspD17Ala fsX55). Case 2 (yellow arrow) had a homozygous
insertion in exon 7 (c.527_528insG p.Gly176Gly fsX59). Markers D15S160, D15S991, and D15S114 were also homozygous; relatives’ DNA
was unavailable for further analysis. wg p Weeks gestation.
inations were performed in all cases with full parental
consent. Genomic DNA was extracted from frozen tissue
in fetal cases and from peripheral blood samples for par-
ents in accordance with standard protocols.
PolymorphicmarkersD15S188, D15S160, D15S991, and
D15S114, ﬂanking the STRA6 gene, were chosen using the
UCSC Genome Browser and were examined in fetal cases
1 and 2 (ﬁg. 1). The parents of case 1 are a consanguineous
couple of Romanian origin, and the parents of case 2 are
a consanguineous couple of Portuguese origin.14 Homo-
zygous haplotypes were demonstrated in each fetus, al-
though the clinically unaffected parents of case 1 had a
heterozygous haplotype with an allele presumably inher-
ited from a common ancestor (DNA was unavailable from
the other family members of case 2).
Primers were subsequently designed to cover the 20 ex-
ons and exon-intron junctions of the STRA6 gene (UCSC
Genome Browser reference sequence NM_022369), in-
cluding exons 1A and 1B (the ﬁrst noncoding exon may
be alternatively spliced), with the use of Primer3 software19
(table 2). PCRs were treated with the ExoSAP enzyme mix
as per themanufacturer’s instructions (GE-Amersham). Se-
quencing was performed for all seven fetal DNA samples
with the use of Big Dye v3.1 Terminator Cycle Sequencing
Reactions on an ABI 3130 (Applied Biosystems). Both the
sense and antisense strands of the PCR-ampliﬁed frag-
ments were analyzedwith Sequence Analysis software (Ap-
plied Biosystems).
Cases 1 and 2 both presented homozygous mutations
in the coding sequence of STRA6 (ﬁg. 1). A homozygous
insertion/deletion in exon 2 (c.50_52delACTinsCC) for fe-
tus 1 causes a frameshift and the appearance of a pre-
mature stop codon (p.Asp17Ala fsX55). An older brother
with isolated bilateral coloboma of the retina and iris was
heterozygous for this mutation, as were the clinically un-
affected parents. Case 2 presented a homozygous single-
base insertion in exon 7 (c.527_528insG) that also predicts
a premature stop codon (p.Gly176Gly fsX59).
Case 4 had six intronic variations and one conservative
amino acid substitution (table 3), all of which were ho-
mozygous and documented SNPs in the general popula-
tion (dbSNP). Parental samples for fetus 4 were not avail-
able for analysis. Since the fetus was not known to come
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Table 3. Sequence Variations in STRA6
Fetal Case and
Nucleotide Change
versus NM_022369
Predicted Effect
on ORF
dbSNP Reference
Number Status
1:
c.50_52delACTinsCC p.Asp17Ala fsX55 … Homozygous
2:
c.527_528insG p.Gly176Gly fsX59 … Homozygous
4:
c.331CrT p.Leu111Leu rs11857410 Homozygous
c.40697ArG … rs34147822 Homozygous
c.406111ArG … rs35255788 Homozygous
c.43024TrA … rs971756 Homozygous
c.43137CrT … rs971757 Homozygous
c.168524TrC … rs12913041 Homozygous
c.184050TrC … rs12912578 Homozygous
5:
c.5969TrG … rs28541560 Heterozygous
c.130143ArC p.Ser472Ser rs351240 Heterozygous
c.1416GrA … rs351241 Heterozygous
6:
c.116632GrA … … Heterozygous
7:
c.116710CrG … rs2277608 Heterozygous
NOTE.—Case 3 had no sequence variations.
from a consanguineous background and had a normal kar-
yotype, the hypothesis of a small, heterozygous deletion
was considered. Quantitative multiplex PCR of small ﬂuo-
rescent fragments (QMPSF)20 was undertaken to measure
the number of genomic STRA6 copies for case 4. The re-
sults indicated that this fetus did not present a deletion
of the STRA6 gene that would explain the observed ho-
mozygosity of the SNPs (data not shown).
A single heterozygous variation located in intron 13
(c.140732GrA) that was observed in case 5 has not
been identiﬁed to date in dbSNP (table 3). We screened
260 control chromosomes without observing the
c.140732GrA variation. The only tissue available from
fetus 5 for expression analysis was a frozen lung sample.
STRA6 transcripts were not observed in either total lung
RNA extracted from an age-matched fetus affected with
an unrelated disorder or from the case 5 tissue sample
(data not shown). Therefore, the consequence of this var-
iation on STRA6 transcription remains to be determined.
We report homozygous mutations in the STRA6 gene
in two fetuses presenting the principal features of MWS,
including bilateral severe microphthalmia and pulmonary
agenesis. Both also had bilateral diaphragmatic eventra-
tion, and one had a cardiac malformation. The observa-
tion that both fetuses came from consanguineous fami-
lies—and, moreover, that one family demonstrated sibling
recurrence—had already evoked a recessive model of in-
heritance for MWS.14 Since the molecular anomaly has
been found, it is now possible to afﬁrm thatMWS is indeed
an autosomal recessive disorder that can be ascribed to
mutations in the STRA6 gene.
These two fetuses with the STRA6 mutation would not
have survived postnatally. In both cases, the mutations
would have led to a truncated protein if translated. Ho-
mozygous STRA6 mutations have also been observed in
peri- and postnatal patients from two other families, as
well as in three sporadic cases with a similar phenotypic
spectrum.18 However, four missensemutations were found
to be associated with a severe clinical phenotype, whereas
two cases with a truncating mutation had milder clinical
signs with no growth retardation nor apparent pulmonary
anomalies. Indeed, one of those patients has survived into
his teens. Comparison of all reported patients with STRA6
mutations (table 1) thus demonstrates that there is no
correlation to date between the nature of a coding mu-
tation and the severity of the phenotype.
The recent functional study of 50 random missensemu-
tations introduced into bovine Stra6 has shown that a few
of these are sufﬁcient to prevent cell surface expression
and that one, although allowing protein insertion into the
membrane, abrogates vitamin A entry into the cell.21 Sim-
ilar studies will now need to be conducted with docu-
mented human mutations to draw conclusions, but it is
probable that phenotypic severity is a result of the reduc-
tion in perceived retinoic acid (RA) dose within sensitive
target tissues, rather than a simple distinction between
missense and nonsense mutations.
We also undertook molecular analysis of STRA6 in ﬁve
other fetuses with pulmonary and ocular or cardiac mal-
formations, but no other patent mutations were identi-
ﬁed, despite some intriguing variations (table 3). The
clinical diversity of patients with STRA6 mutations, and
the large phenotypic overlap with those who do not
have the mutations, strongly suggests that MWS and re-
lated syndromes are not only clinically but genetically
heterogeneous.
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The only necessary diagnostic criterion predicting the
involvement of STRA6, on the basis of the patients cur-
rently reported here and in the previous study,18 is severe
microphthalmia (clinical anophthalmia).Microphthalmia
with any macroscopically residual presence of the ocular
globe does not correlate with STRA6 mutations in either
series (table 1). Obviously, since many genes have previ-
ously been identiﬁed in both isolated and syndromic mi-
crophthalmia, this feature is not sufﬁcient to direct mo-
lecular testing. The severe eye malformations subsequent
to STRA6 mutations are always observed in association
with one or more of the three following signs: pulmonary
defects, congenital diaphragmatic eventration/hernia, or
cardiovascular malformation involving the common aor-
ticopulmonary trunk or pulmonary arteries. Furthermore,
according to our two MWS cases and descriptions of MWS
in the literature, pancreatic malformations and IUGRmay
also be secondary diagnostic criteria.
Pulmonary defects range from agenesis (this report) to
hypoplasia or unilobar lung (among families with MWS
mutations) to no obvious lung problems (in either mem-
ber of family 2 examined by Pasutto et al).18 Pulmonary
and diaphragmatic malformations (eventration/hernia)
are not always associated and occur separately or in com-
bination even among members of the same family.18 This
observation leads us to conclude that, in the context of
STRA6 mutations, the pulmonary phenotype of patients
with mutations is a primary malformation and is not a
consequence of diaphragmatic hernia. However, the joint
presence of clinical anophthalmia and pulmonary and/or
diaphragmatic anomalies is still not sufﬁcient to guarantee
STRA6 involvement, because other cases with bilateral an-
ophthalmia and hypoplastic lungs (patients with MWS
GM23728 and CD50396 from Pasutto et al.18 and our case
4) do not present coding-sequence mutations (table 1).
Cardiovascular involvement is frequent but inconstant.
Case 2 had a ventricular septal defect and pulmonary
trunk agenesis, whereas case 1 presented isolated agenesis
of the pulmonary arteries. Furthermore, STRA6 mutations
described by Pasutto et al. also give rise to conotruncal or
great-artery malformations (i.e., truncus arteriosus, tetra-
logy of Fallot, pulmonary valve or arterial stenosis, and
right aortic arch) in at least some family members.18 Other
affected members with identical mutations had no car-
diovascular signs (cf. MWS4-BE). Cases of MWS described
elsewhere9,12 also show a preponderance of pulmonary
artery absence, ductus arteriosus, or ventricular septal
defects.
Fryns syndrome (MIM 229850) has a clinical spectrum
that includes diaphragmatic hernia and, less frequently,
microphthalmia, facial dysmorphy, and distal limb anom-
alies. Fetal case 3, presenting with bilateral microphthal-
mia, pulmonary hypoplasia, diaphragmatic hernia, car-
diac involvement, and cleft palate, was given a diagnosis
of Fryns syndrome. Despite the implication of the same
organ systems as in MWS and absence of a digital phe-
notype, no mutations in the STRA6 coding sequence were
found. Patients GM23728 and CD50396 from Pasutto et
al.18 also had a similar phenotype (table 1); the latter was
given a diagnosis of MWS, presented true clinical an-
ophthalmia, and had a cleft palate. Palate involvement
might therefore be suggestive of Fryns syndrome rather
than MWS. Phenotypic overlap between these two dis-
orders indicates that similar cases given a diagnosis of
Fryns syndrome or MWS have either a noncoding mu-
tation in STRA6 or involvement of another gene necessary
for the cellular interpretation of RA levels. For some au-
thors, animal models of retinoid deﬁciency also evoke the
PAGOD syndrome (pulmonary tract and pulmonary ar-
tery, agonadism, omphalocele, diaphragmatic defect, and
dextrocardia [MIM 202660]), which shares features with
Fryns syndrome and MWS.22
RA, a small lipophilic hormone derived from retinol (vi-
tamin A), is a ligand for nuclear receptors (RARa, -b, and
-g) that act in homodimers or in heterodimers with reti-
noid X receptor partners to bind DNA and regulate the
expression of many genes, including the Stra (stimulated
by retinoic acid) targets.23,24 The functionally identiﬁed
Stra genes have different roles and structurally unrelated
products. For example, Stra1 encodes ephrin B1, a bidi-
rectional, membrane-bound signalingmolecule highly ex-
pressed in the embryonic neural crest25; Stra7, later iden-
tiﬁed as the evolutionarily conserved transcription factor
Gbx2,26 partners with the homeobox transcription factor
Otx2 in the speciﬁcation of the isthmic organizer (mid-
brain/hindbrain junction).27
Otx2 was also subsequently identiﬁed as a transcrip-
tional target of RA, which leads to derepression of Pax6
transcription in the optic cup.28 Interestingly, bothOTX229
and PAX64 are responsible for human anophthalmias
(MIM 610125 and 607108 [allelic variant .0005], respec-
tively), through heterozygous loss-of-function with in-
complete penetrance for the former and compound het-
erozygous loss-of-function engendering a primary anoph-
thalmia for the latter. Mutations in EFNB1 (encoding hu-
man ephrin B1) induce craniofrontonasal syndrome (MIM
304110), sometimes in association with congenital dia-
phragmatic hernia (CDH).30,31 We note that CRABP1 (cel-
lular retinoic acid–binding protein 1), another transcrip-
tional target and effector of cytoplasmic RA levels,32 is
located close to reported CDH loci in the long arm of
chromosome 15. Experimental or teratogenic reductions
in RA levels also lead to CDH in both animals and
humans.33,34
The murine Stra6 gene encodes an integral transmem-
brane protein that is expressed in the developing eye,
lung, other endodermal gut derivatives, limbs, and so-
mites.23 In addition to being stimulated by RA, Stra6 en-
codes a receptor for soluble retinol-binding protein, efﬁ-
ciently mediating retinol uptake from the circulatory
system into target cells.21
Signaling by RA within the caudal pharyngeal endo-
derm of the vertebrate embryo is critical for the organi-
zation of the adjacent aortic arch vessels and heart. Sen-
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sitivity of only the most posterior aortic arches, which
persist in direct continuity with the outﬂow tract of the
heart, may be a result of the localized mesodermal pro-
duction of retinaldehyde dehydrogenase 2 (Raldh2), a
major enzyme for RA synthesis from retinol during de-
velopment.35 Raldh2/ mice demonstrate third- and
fourth-arch artery malformations, with agenesis of the
sixth arch36 in addition to cardiac septation defects37 and
partial pancreatic agenesis.38 The variable implication of
the cardiac outﬂow tract and vascular derivatives of the
embryonic fourth (deﬁnitive aorta) and sixth (ductus ar-
teriosus and proximal pulmonary artery) aortic arches in
our patients is consistent with an underlying ﬁeld defect
affecting the perception of RA dose by the endoderm.
Indeed, murine Stra6 is highly expressed in the pharyn-
geal endoderm and mesenchyme along the embryonic
gut.23 Our two severely affected patients with mutations
had duodenal stenosis and pancreatic malformations in
addition to lung agenesis. These organs are among the
many derivatives of the embryonic endoderm produced
by localized outpocketings into the mesoderm that will
consolidate into the deﬁnitive structure.
RA is particularly necessary for normal growth and for-
mation of the lung. Fgf10/ mice demonstrate complete
lung agenesis,15,16 whereas, in knockout mice for the ap-
propriate Fgf10-binding isoform of Fgfr2, the tracheal bi-
furcation at the origin of the bronchi is absent.17 In
Raldh2/ mouse embryos, Fgf10 is no longer expressed in
the lung bud, and complete agenesis results.39 It appears
likely that Stra6 expressed, among other places, in the
Raldh2 bronchial mesenchyme of the early lung23 me-
diates retinol entry into the mesoderm and a subsequent
effect on Fgfr2 signaling in the endoderm. Indeed, the
supply of exogenous RA for short periods can partially
rescue both Fgf10 expression and lung agenesis, leading
to unilobar or unilateral right-sided lung development;
longer rescue periods lead to better recovery and more
subtle alveolar malformations.40
Stra6 is also expressed at all stages of eye development—
initially, within the optic vesicle and, later, within the
periocular mesenchyme, the choroid, and the optic nerve
(and forebrain) meninges. Expression in the retinal pig-
ment epithelium persists throughout adult life in both
mice and humans,18,23 which is indicative of the continued
need for RA for ocular function. The consistency of clinical
anophthalmia in patients with STRA6 mutations argues
for the need for vitamin A uptake to further all stages of
eye development after initial optic speciﬁcation.
Stra6 transcripts are also detected in several other sites,
including the forebrain, the isthmic organizer, and the
neurohypophysis. However, no patients with STRA6 mu-
tations present CNSmalformations or pituitary anomalies,
although IUGR or short stature may indicate amore subtle
effect (table 1). Murine expression patterns do not always
sufﬁce to explain clinical outcome.41 Despite the strong,
localized brain expression of the RA target Gbx2 (Stra7),
its absence in mice gives rise only to posterior branchial
arch anomalies and cardiac malformations, reminiscent
of those observed in patients with STRA6 mutations or in
Raldh2/ mice.42 There may also be species-speciﬁc dif-
ferences in the RA sensitivity of the developing brain; the
clinical spectrum of human vitamin A deﬁciency syn-
drome does not include the exencephaly observed in
mouse models.43
In conclusion, STRA6 mutations are responsible for a
large spectrum of congenital malformations with no cur-
rent evidence of a genotype-phenotype correlation. Dif-
ferent transcriptional targets of RA signaling in humans
appear to effect subset phenotypes of those observed in
more generalized deﬁciencies.43 MWS is thus part of a
growing family of human syndromes due to mutations in
genes encoding effectors of the powerful developmental
morphogen, RA.
Acknowledgments
The authors warmly thank Chantal Esculpavit, Annie Ebrac, Ge´r-
aldine Goudefroye, and Catherine Ozilou, for their assistance,
and Jeanne Amiel and Patrick Calvas, for critical discussion and
reﬂection. Support has been provided by National Institutes of
Health grant R01 NS039818-09 (to M.V. and S.T.) and the Asso-
ciation Franc¸aise contre les Myopathies (to H.E.), in addition to
the Assistance Publique and the Institut National de la Sante´ et
de la Recherche Me´dicale.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for syndromic microphthalmias, an-
ophthalmia, anophthalmia and pulmonary hypoplasia, MWS,
Fryns syndrome, PAGOD syndrome, and craniofrontonasal
syndrome)
PAX6 Allelic Variant Database, http://pax6.hgu.mrc.ac.uk/
Primer3 software, http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi
UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/
hgTracks (for reference sequence NM_022369)
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